StockMacro
Menu

Revolution Medicines

$161.20 +4.1% in 6 monthsMarket cap $34.9B

RVMD on XNAS, Health Care, Revolution Medicines, Inc., job postings

Measures activity, not value. Not investment advice.

Shares up 131% in a year, but the company lost $1.9B and insiders sold $89.9M in 90 days.

  • BadShort interest at 6.0% of shares, 7.8 days to cover
  • GoodNew institutional positions rose to 132, 2.3 times a year earlier

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
883
Website
revmed.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $197.6M, net loss $407.5M.
Quarter to 31 Dec 2021: revenue $9.5M, net income -$52.7MQuarter to 31 Dec 2021: revenue $9.5M, net income -$52.7MQuarter to 31 Mar 2022: revenue $7.6M, net income -$57.6MQuarter to 31 Mar 2022: revenue $7.6M, net income -$57.6MQuarter to 30 Jun 2022: revenue $9.1M, net income -$61.2MQuarter to 30 Jun 2022: revenue $9.1M, net income -$61.2MQuarter to 30 Sep 2022: revenue $3.4M, net income -$73.3MQuarter to 30 Sep 2022: revenue $3.4M, net income -$73.3MQuarter to 31 Dec 2022: revenue $15.3M, net income -$56.5MQuarter to 31 Dec 2022: revenue $15.3M, net income -$56.5MQuarter to 31 Mar 2023: revenue $7.0M, net income -$68.1MQuarter to 31 Mar 2023: revenue $7.0M, net income -$68.1MQuarter to 30 Jun 2023: revenue $3.8M, net income -$98.3MQuarter to 30 Jun 2023: revenue $3.8M, net income -$98.3MQuarter to 30 Sep 2023: revenue $0, net income -$108.4MQuarter to 30 Sep 2023: revenue $0, net income -$108.4MQuarter to 31 Dec 2023: revenue $742K, net income -$161.5MQuarter to 31 Dec 2023: revenue $742K, net income -$161.5MQuarter to 31 Mar 2024: revenue $0, net income -$116.0MQuarter to 31 Mar 2024: revenue $0, net income -$116.0MQuarter to 30 Jun 2024: revenue $0, net income -$133.2MQuarter to 30 Jun 2024: revenue $0, net income -$133.2MQuarter to 30 Sep 2024: revenue $0, net income -$156.3MQuarter to 30 Sep 2024: revenue $0, net income -$156.3MQuarter to 31 Dec 2024: revenue $0, net income -$194.6MQuarter to 31 Dec 2024: revenue $0, net income -$194.6MQuarter to 31 Mar 2025: revenue –, net income -$213.4MQuarter to 30 Jun 2025: revenue –, net income -$247.8MQuarter to 30 Sep 2025: revenue $0, net income -$305.2MQuarter to 30 Sep 2025: revenue $0, net income -$305.2MQuarter to 31 Dec 2025: revenue $0, net income -$364.9MQuarter to 31 Dec 2025: revenue $0, net income -$364.9MQuarter to 31 Mar 2026: revenue –, net income -$453.8MQuarter to 30 Jun 2026: revenue –, net income -$644.4MQuarter to 30 Sep 2026: revenue $197.6M, net income -$407.5MQuarter to 30 Sep 2026: revenue $197.6M, net income -$407.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $644.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$197.6M-$407.5M
30 Jun 2026–-$644.4M
31 Mar 2026–-$453.8M
31 Dec 2025$0-$364.9M
30 Sep 2025$0-$305.2M
30 Jun 2025–-$247.8M
31 Mar 2025–-$213.4M
31 Dec 2024$0-$194.6M
30 Sep 2024$0-$156.3M
30 Jun 2024$0-$133.2M
31 Mar 2024$0-$116.0M
31 Dec 2023$742K-$161.5M
30 Sep 2023$0-$108.4M
30 Jun 2023$3.8M-$98.3M
31 Mar 2023$7.0M-$68.1M
31 Dec 2022$15.3M-$56.5M
30 Sep 2022$3.4M-$73.3M
30 Jun 2022$9.1M-$61.2M
31 Mar 2022$7.6M-$57.6M
31 Dec 2021$9.5M-$52.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$1.9B -$961.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$9.14 -$5.18
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -93.6% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$1.4B -$777.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $3.7B $1.9B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $487.9M –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$3.2B (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.20 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $11.10
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 14.5 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Revolution MedicinesRVMD (this company) $34.9Bloss–––
BiogenBIIB $36.9B1063.6+2.3%3.4%
ExelixisEXEL $15.8B17.86.3+9.1%35.5%
ModernaMRNA $78.9Bloss31.2+13%-110%
Neurocrine BiosciencesNBIX $15.2B21.74.1+38%19.0%
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$89.9M

bought $0, sold $89.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.9%

745 13F filers vs 678

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

98%

212.0M shares held by 13F filers (30 Sep 2026) of 216.3M outstanding (30 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

6.0%

13.1M shares sold short (30 Oct 2026) of 216.3M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.8

13.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+1.1%

12.9M shares sold short in the report before, 13.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

69%

69% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

360

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+154%

33 vs 13 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+10%

$3.7M vs $3.3M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

41

41 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.3×

41 articles in the last 7 days; its usual week has 6.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $197.6M
  • New institutional positions 132, 2.3× a year earlier

Price $161.20 on 20 Nov 2026, +131% over 12 months (12-month range $69.88 to $221.15)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $154.8M in the last 12 months (the 12 months before: $34.9M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 33 published in the last 12 months, +154% on the 12 months before.
Revenue per quarter. Revenue $197.6M in the latest quarter.
Capital spending per quarter. Capital spending $3.7M in the latest quarter, +10% on a year earlier.
Institutional holders (13F filers). 745 13F filers reported holding it in the latest 13F quarter, +142% on a year earlier.
Federal obligations. Federal obligations: $15K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 132 vs usual 55 (2026-09-30); 2.3x the same period a year earlier
5 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 197.6M vs usual 0 (2026-09-30)
22 Jun 20268-K and other filingsDirector or officer change
22 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 146 vs usual 46 (2026-03-31); 3.4x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 86 vs usual 44 (2025-12-31); 2.0x the same period a year earlier
7 Aug 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 7.5M vs usual 2.5M (2025-06-30); 3.1x the same period a year earlier
18 Jun 20258-K and other filingsDirector or officer change
18 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Aug 20248-K and other filingsDirector or officer change
7 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Nov 20238-K and other filingsDirector or officer change
9 Nov 20238-K and other filingsCompleted an acquisition or asset sale
5 Sep 20238-K and other filingsDirector or officer change
5 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Feb 2023Sharp changeQuarterly revenue change: quarterly revenue change, 15.3M vs usual 8.7M (2022-12-31); 1.6x the same period a year earlier
7 Dec 20228-K and other filingsA major agreement ended
1 Sep 20228-K and other filingsDirector or officer change
13 Jul 20228-K and other filingsDirector or officer change
10 Jun 20228-K and other filingsDirector or officer change
10 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$69K published
Month from 1 Mar 2022: $44.1M published
Month from 1 Jun 2022: -$8.6M published
Month from 1 Jul 2022: $6.0M published
Month from 1 Sep 2022: -$71K published
Month from 1 Oct 2022: -$358K published
Month from 1 Nov 2022: -$721K published
Month from 1 Dec 2022: -$87K published
Month from 1 Mar 2023: $14.1M published
Month from 1 Jun 2023: -$167K published
Month from 1 Aug 2023: -$1.2M published
Month from 1 Sep 2023: -$3.6M published
Month from 1 Oct 2023: -$1.4M published
Month from 1 Nov 2023: -$33K published
Month from 1 Dec 2023: -$1.6M published
Month from 1 Jan 2024: -$525K published
Month from 1 Mar 2024: -$1.3M published
Month from 1 Apr 2024: -$699K published
Month from 1 May 2024: -$459K published
Month from 1 Jun 2024: -$2.1M published
Month from 1 Jul 2024: -$2.5M published
Month from 1 Aug 2024: -$1.2M published
Month from 1 Sep 2024: -$1.8M published
Month from 1 Oct 2024: -$6.4M published
Month from 1 Nov 2024: -$5.6M published
Month from 1 Dec 2024: $58.9M published
Month from 1 Jan 2025: -$97K published
Month from 1 Mar 2025: -$915K published
Month from 1 Jun 2025: -$1.2M published
Month from 1 Sep 2025: -$7.4M published
Month from 1 Oct 2025: -$2.9M published
Month from 1 Nov 2025: -$11.5M published
Month from 1 Dec 2025: -$2.4M published
Month from 1 Jan 2026: -$8.6M published
Month from 1 Mar 2026: -$10.4M published
Month from 1 Apr 2026: -$18.4M published
Month from 1 May 2026: -$481K published
Month from 1 Jun 2026: -$23.5M published
Month from 1 Jul 2026: -$1.0M published
Month from 1 Aug 2026: -$29.9M published
Month from 1 Sep 2026: -$46.8M published
Month from 1 Oct 2026: -$1.7M published
Month from 1 Nov 2026: -$11.4M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 3 published
Quarter from 1 Jul 2022: 4 published
Quarter from 1 Oct 2022: 1 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2023: 9 published
Quarter from 1 Jul 2023: 4 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2024: 5 published
Quarter from 1 Jul 2024: 8 published
Quarter from 1 Oct 2024: 5 published
Quarter from 1 Jan 2025: 3 published
Quarter from 1 Apr 2025: 2 published
Quarter from 1 Jul 2025: 4 published
Quarter from 1 Oct 2025: 4 published
Quarter from 1 Jan 2026: 5 published
Quarter from 1 Apr 2026: 6 published
Quarter from 1 Jul 2026: 16 published
Quarter from 1 Oct 2026: 6 published
Revenue per quarter
Quarter ended 31 Dec 2021: $9.5M, +8.1% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $7.6M, -25% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $9.1M, +4.8% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $3.4M, +205% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $15.3M, +62% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $7.0M, -7.4% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $3.8M, -58% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $742K, -95% on a year earlier; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 27 Feb 2025
Quarter ended 30 Sep 2025: $0; public on 5 Nov 2026
Quarter ended 31 Dec 2025: $0; public on 26 Feb 2026
Quarter ended 30 Sep 2026: $197.6M; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $1.2M, +1.2% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $1.9M, -47% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $2.5M, +93% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $3.5M, +676% on a year earlier; public on 8 Nov 2022
Quarter ended 31 Dec 2022: $2.9M, +143% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $1.8M, -6.9% on a year earlier; public on 9 May 2023
Quarter ended 30 Jun 2023: $1.1M, -56% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $2.5M, -28% on a year earlier; public on 7 Nov 2023
Quarter ended 31 Dec 2023: $2.3M, -19% on a year earlier; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $3.2M, +80% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $2.4M, +114% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $3.5M, +39% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $1.2M, -47% on a year earlier; public on 27 Feb 2025
Quarter ended 31 Mar 2025: $3.3M, +3.1% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $7.5M, +211% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $3.3M, -4.9% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $1.9M, +58% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $1.5M, -53% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $2.3M, -69% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $3.7M, +10% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 109; public on 14 Feb 2022
31 Mar 2022 report: 118; public on 16 May 2022
30 Jun 2022 report: 128; public on 15 Aug 2022
30 Sep 2022 report: 134; public on 14 Nov 2022
31 Dec 2022 report: 130; public on 14 Feb 2023
31 Mar 2023 report: 144; public on 15 May 2023
30 Jun 2023 report: 131; public on 14 Aug 2023
30 Sep 2023 report: 158; public on 14 Nov 2023
31 Dec 2023 report: 175; public on 14 Feb 2024
31 Mar 2024 report: 199; public on 15 May 2024
30 Jun 2024 report: 207; public on 14 Aug 2024
30 Sep 2024 report: 241; public on 14 Nov 2024
31 Dec 2024 report: 273; public on 14 Feb 2025
31 Mar 2025 report: 273; public on 15 May 2025
30 Jun 2025 report: 293; public on 14 Aug 2025
30 Sep 2025 report: 308; public on 14 Nov 2025
31 Dec 2025 report: 377; public on 17 Feb 2026
31 Mar 2026 report: 504; public on 15 May 2026
30 Jun 2026 report: 678; public on 14 Aug 2026
30 Sep 2026 report: 745; public on 16 Nov 2026
Federal obligations
Month from 1 Oct 2026: $15K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year; it also saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Quarterly revenue change: reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year Public on 5 Nov 2026.
  • Many funds opening a new position: saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year Public on 16 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $154.8M in the last 12 months (the 12 months before: $34.9M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 22 sales, $89.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Stephen Michael KelseySee RemarksSellplanned in advance (10b5-1); after exercising options27,160$167.86$4.6MForm 4
13 Nov 2026Jack AndersChief Financial OfficerSellplanned in advance (10b5-1); after exercising options35,750$188.10$6.7MForm 4
12 Nov 2026Anthony ManciniSee RemarksSellplanned in advance (10b5-1); after exercising options811$200.00$162KForm 4
28 Oct 2026Anthony ManciniSee RemarksSellplanned in advance (10b5-1); after exercising options2,310$186.99$432KForm 4
1 Oct 2026Alan B. SandlerChief Development OfficerSellplanned in advance (10b5-1); after exercising options6,309$202.14$1.3MForm 4
29 Sep 2026Jeff CisliniSVP & General CounselSellplanned in advance (10b5-1)765$207.32$159KForm 4
28 Sep 2026Anthony ManciniSee RemarksSellplanned in advance (10b5-1); after exercising options3,708$200.45$743KForm 4
24 Sep 2026Elizabeth M AndersonDirectorSellplanned in advance (10b5-1); after exercising options10,143$193.04$2.0MForm 4

745 institutions reported shares at the end of Q3 2026, 98% of the shares outstanding; 131 opened a position, 68 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)15.4M7.12%$3.2B+3.2M+26%
BlackRock, Inc.13.9M6.41%$2.8B+162K+1.2%
Farallon Capital Management, L.L.C.13.4M6.20%$2.8B-132K-1.0%
Baker Bros. Advisors LP10.6M4.92%$2.2B-806K-7.0%
Darwin Global Management, Ltd.10.6M4.91%$2.2BNo change
Vanguard Capital Management LLC9.1M4.23%$1.9B+61K+0.7%
Vanguard Portfolio Management LLC8.2M3.77%$1.7B-138K-1.7%
Nextech Invest Ltd.7.6M3.51%$1.6BNo change
Janus Henderson Group Ltd.7.6M3.50%$1.6B
Paradigm Biocapital Advisors LP6.2M2.88%$1.3B-142K-2.2%

Company events

All 28 company events

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Sep 2026Signed a major agreementSame filing: took on new debt8-K
22 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
17 Apr 2026Signed a major agreementSame filing: took on new debt8-K
24 Jun 2025Signed a major agreementSame filing: took on new debt8-K
18 Jun 2025Director or officer change8-K
7 Aug 2024Director or officer change8-K
9 Nov 2023Director or officer change; Completed an acquisition or asset saleSame filing: shareholder vote results8-K
5 Sep 2023Director or officer change8-K

360 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 21%, Legal, policy & compliance 17%, Program & project management 15%, Operations & administration 11%.

PostedJobLocation
21 Nov 2026Senior Manager, Global Patient Safety OperationsOperations & administrationRedwood City, California, United States
21 Nov 2026Senior Manager, Global Case Management, Global Patient Safety OperationsOperations & administrationRedwood City, California, United States
21 Nov 2026Senior Director, Clinical Supply ChainSupply chain & procurementRedwood City, California, United States
21 Nov 2026Vice President, Global Medical Affairs Engagement, Analytics and CapabilitiesData & analyticsRemote (United States)
21 Nov 2026Senior Scientist I, Process ChemistryResearch & scienceRedwood City, California, United States
21 Nov 2026Vice President, Global Analytics and InsightsData & analyticsRemote (United States)
21 Nov 2026Director, Stakeholder Engagement, Congress Strategy & Operations, CongressesOperations & administrationRedwood City, California, United States
21 Nov 2026Associate Director, Portfolio Operations ExcellenceOperations & administrationRemote (United States)

The 5 newest of 368 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Revolution Medicines (RVMD): reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year, while it saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year. Two unrelated kinds of activity within 12 days.

  • Financials: Quarterly revenue change, became public on 5 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2023-12-31: $742K2024-03-31: $02024-06-30: $02024-09-30: $02024-12-31: $02025-09-30: $02025-12-31: $02026-09-30: $197.6M
The quarter ended 30 Sep 2026 against the 7 quarters before it. this quarterearliernormal: $0
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 5 Nov 2026

Revolution Medicines reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year.

This period
$197.6M (the quarter ended 30 Sep 2026)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+197.6
Same quarter last year
$0
History used
2,740 days
2023-12-31: $742K2024-03-31: $02024-06-30: $02024-09-30: $02024-12-31: $02025-09-30: $02025-12-31: $02026-09-30: $197.6M
the quarter ended 30 Sep 20267 earlier quartersnormal: $0

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

Revolution Medicines saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year.

This period
132 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
55
Typical spread (median absolute deviation)
12
How far from its usual level
+4.3
Same quarter last year
57
History used
2,374 days
2024-09-30: 472024-12-31: 432025-03-31: 432025-06-30: 532025-09-30: 572025-12-31: 862026-03-31: 1462026-06-30: 2242026-09-30: 132
the quarter ended 30 Sep 20268 earlier quartersnormal: 55

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year, while it saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year. Two unrelated kinds of activity within 12 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 5 Nov 2026

    Revolution Medicines reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year.

    This period
    $197.6M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 7 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +197.6
    Same quarter last year
    $0
    History used
    2,740 days
    2023-12-31: $742K2024-03-31: $02024-06-30: $02024-09-30: $02024-12-31: $02025-09-30: $02025-12-31: $02026-09-30: $197.6M
    the quarter ended 30 Sep 20267 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    Revolution Medicines saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year.

    This period
    132 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    55
    Typical spread (median absolute deviation)
    12
    How far from its usual level
    +4.3
    Same quarter last year
    57
    History used
    2,374 days
    2024-09-30: 472024-12-31: 432025-03-31: 432025-06-30: 532025-09-30: 572025-12-31: 862026-03-31: 1462026-06-30: 2242026-09-30: 132
    the quarter ended 30 Sep 20268 earlier quartersnormal: 55

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 132 13F filers open a new position in the quarter ended 30 Sep 2026, 2.3× the same quarter last year.

    Same quarter last year: 57; its normal quarter is 55.

    See the evidence
    This period
    132 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    55
    Typical spread (median absolute deviation)
    12
    How far from its usual level
    +4.3
    Same quarter last year
    57
    History used
    2,374 days
    2024-09-30: 472024-12-31: 432025-03-31: 432025-06-30: 532025-09-30: 572025-12-31: 862026-03-31: 1462026-06-30: 2242026-09-30: 132
    the quarter ended 30 Sep 20268 earlier quartersnormal: 55

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 12 Nov 2026Institutional holdings record

    Winslow Capital Management, LLC opened a $260.0M position (2026Q3 13F)

  4. 5 Nov 2026Financials change

    reported revenue of $197.6M for the quarter ended 30 Sep 2026, against none in the same quarter last year.

    See the evidence
    This period
    $197.6M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 7 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +197.6
    Same quarter last year
    $0
    History used
    2,740 days
    2023-12-31: $742K2024-03-31: $02024-06-30: $02024-09-30: $02024-12-31: $02025-09-30: $02025-12-31: $02026-09-30: $197.6M
    the quarter ended 30 Sep 20267 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  5. 12 Aug 2026Institutional holdings record

    Capital World Investors opened a $751.0M position (2026Q2 13F)

  6. 3 Aug 2026Institutional holdings record

    MASSACHUSETTS FINANCIAL SERVICES CO /MA/ opened a $377.0M position (2026Q2 13F)

  7. 22 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 22 Jun 2026Filings record

    Director or officer change

  9. 15 May 2026Institutional holdings change

    saw 146 13F filers open a new position in the quarter ended 31 Mar 2026, 3.4× the same quarter last year.

    Same quarter last year: 43; its normal quarter is 46.

    See the evidence
    This period
    146 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    46
    Typical spread (median absolute deviation)
    5
    How far from its usual level
    +13.5
    Same quarter last year
    43
    History used
    2,191 days
    2024-03-31: 452024-06-30: 382024-09-30: 472024-12-31: 432025-03-31: 432025-06-30: 532025-09-30: 572025-12-31: 862026-03-31: 146
    the quarter ended 31 Mar 20268 earlier quartersnormal: 46

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  10. 17 Feb 2026Institutional holdings change

    saw 86 13F filers open a new position in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.

    Same quarter last year: 43; its normal quarter is 44.

    See the evidence
    This period
    86 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    44
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +9.5
    Same quarter last year
    43
    History used
    2,101 days
    2023-12-31: 432024-03-31: 452024-06-30: 382024-09-30: 472024-12-31: 432025-03-31: 432025-06-30: 532025-09-30: 572025-12-31: 86
    the quarter ended 31 Dec 20258 earlier quartersnormal: 44

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 7 Aug 2025Financials change

    spent $7.5M on capital projects in the quarter ended 30 Jun 2025, 3.1× the same quarter last year.

    Same quarter last year: $2.4M; its normal quarter is $2.5M.

    See the evidence
    This period
    $7.5M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $2.5M
    Typical spread (median absolute deviation)
    $750K
    How far from its usual level
    +4.5
    Same quarter last year
    $2.4M
    History used
    2,283 days
    2023-06-30: $1.1M2023-09-30: $2.5M2023-12-31: $2.3M2024-03-31: $3.2M2024-06-30: $2.4M2024-09-30: $3.5M2024-12-31: $1.2M2025-03-31: $3.3M2025-06-30: $7.5M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $2.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 18 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 18 Jun 2025Filings record

    Director or officer change

  14. 10 Dec 2024Insiders record

    Schroeder Thilo (director) bought 1,304,347 shares of RVMD ($60.0M) (dated 9 Dec 2024)

  15. 7 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 7 Aug 2024Filings record

    Director or officer change

  17. 9 Nov 2023Filings record

    Director or officer change

  18. 9 Nov 2023Filings record

    Completed an acquisition or asset sale

  19. 5 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 5 Sep 2023Filings record

    Director or officer change

  21. 11 Mar 2023Insiders record

    Schroeder Thilo (director) bought 650,000 shares of RVMD ($14.1M) (dated 10 Mar 2023)

  22. 28 Feb 2023Financials change

    reported revenue of $15.3M for the quarter ended 31 Dec 2022, 1.6× the same quarter last year.

    Same quarter last year: $9.5M; its normal quarter is $8.7M.

    See the evidence
    This period
    $15.3M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $8.7M
    Typical spread (median absolute deviation)
    $941K
    How far from its usual level
    +4.7
    Same quarter last year
    $9.5M
    History used
    1,371 days
    2020-12-31: $8.8M2021-03-31: $10.1M2021-06-30: $8.7M2021-09-30: $1.1M2021-12-31: $9.5M2022-03-31: $7.6M2022-06-30: $9.1M2022-09-30: $3.4M2022-12-31: $15.3M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $8.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 7 Dec 2022Filings record

    A major agreement ended

  24. 1 Sep 2022Filings record

    Director or officer change

  25. 27 Jul 2022Insiders record

    Schroeder Thilo (director) bought 250,000 shares of RVMD ($5.0M) (dated 26 Jul 2022)

  26. 26 Jul 2022Insiders record

    Kim Lorence H. (director) bought 50,000 shares of RVMD ($1.0M) (dated 25 Jul 2022)

  27. 13 Jul 2022Filings record

    Director or officer change

  28. 10 Jun 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  29. 10 Jun 2022Filings record

    Director or officer change

  30. 30 Mar 2022Insiders record

    Schroeder Thilo (director) bought 42,725 shares of RVMD ($1.1M) (dated 29 Mar 2022)

  31. 25 Mar 2022Insiders record

    Schroeder Thilo (director) bought 232,364 shares of RVMD ($5.5M) (dated 24 Mar 2022)

  32. 22 Mar 2022Insiders record

    Schroeder Thilo (director) bought 168,051 shares of RVMD ($3.4M) (dated 21 Mar 2022)

  33. 15 Mar 2022Insiders record

    Schroeder Thilo (director) bought 43,510 shares of RVMD ($897,763) (dated 14 Mar 2022)

  34. 10 Mar 2022Insiders record

    Schroeder Thilo (director) bought 246,438 shares of RVMD ($4.7M) (dated 9 Mar 2022)

  35. 5 Mar 2022Insiders record

    Schroeder Thilo (director) bought 1,088,227 shares of RVMD ($28.6M) (dated 4 Mar 2022)

  36. 16 Nov 2021Financials change

    reported revenue of $1.1M for the quarter ended 30 Sep 2021, 91% below the same quarter last year.

    Same quarter last year: $12.7M; its normal quarter is $10.8M.

    See the evidence
    This period
    $1.1M (the quarter ended 30 Sep 2021)
    Normal quarter (median of 8 earlier)
    $10.8M
    Typical spread (median absolute deviation)
    $1.5M
    How far from its usual level
    -4.5
    Same quarter last year
    $12.7M
    History used
    914 days
    2019-09-30: $12.5M2019-12-31: $12.1M2020-03-31: $11.5M2020-06-30: $10.0M2020-09-30: $12.7M2020-12-31: $8.8M2021-03-31: $10.1M2021-06-30: $8.7M2021-09-30: $1.1M
    the quarter ended 30 Sep 20218 earlier quartersnormal: $10.8M

    Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  37. 25 Mar 2021Short interest and volume change

    had 5.8M shares sold short in the 15 Mar 2021 report, 4.2× the same report last year.

    Same report last year: 1.4M; its normal report is 1.9M.

    See the evidence
    This period
    5.8M (the 15 Mar 2021 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    481K
    How far from its usual level
    +5.6
    Same report last year
    1.4M
    History used
    381 days
    2020-03-13: 1.4M2020-03-31: 1.6M2020-04-15: 1.7M2020-04-30: 1.7M2020-05-15: 1.8M2020-05-29: 1.7M2020-06-15: 1.5M2020-06-30: 1.6M2020-07-15: 1.4M2020-07-31: 1.5M2020-08-14: 1.4M2020-08-31: 1.7M2020-09-15: 2.0M2020-09-30: 3.4M2020-10-15: 2.9M2020-10-30: 3.3M2020-11-13: 3.1M2020-11-30: 2.6M2020-12-15: 2.7M2020-12-31: 3.4M2021-01-15: 4.0M2021-01-29: 4.2M2021-02-12: 5.2M2021-02-26: 5.4M2021-03-15: 5.8M
    the 15 Mar 2021 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 8 Mar 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 8 Mar 2021Filings record

    Director or officer change

  40. 3 Feb 2021Filings record

    Registered new securities for sale (S-1)

Showing the newest 40 of 52 entries; narrow the window or the kind of data to see older ones.

Not listed: 332 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001628171
Ticker
RVMD
Domain
revmed.com
Employer name
REVOLUTION MEDICINES, INC. (1 unverified)
Hq location
CA|REDWOOD CITY|94063 (1 unverified)
Name
EQRx, LLC, Revolution Medicines, Inc., Revolution Medicines Japan KK, Revolution Medicines Netherlands B.V and 3 more
Uei
LNAMTJN6UQE7
Wikidata
Q107518109
  • DOL H-1B labor condition applications and PERM certifications323 data points24 Feb 2020 to 21 Sep 2026
  • SEC Form 13F institutional holdings3 records, 243 data points31 Mar 2020 to 12 Nov 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)108 records21 Dec 2016 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)477 data points31 Dec 2017 to 30 Oct 2026
  • SEC Form 4 insider transactions257 records, 556 data points18 Feb 2020 to 18 Nov 2026
  • FINRA short interest (twice monthly)479 data points28 Feb 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3406 data points13 Feb 2020 to 20 Nov 2026
  • USASpending.gov federal awards3 data points6 Oct 2026 to 6 Oct 2026